West Pharmaceutical Services (NYSE:WST) Shares Gap Up Following Strong Earnings

West Pharmaceutical Services, Inc. (NYSE:WST)’s share price gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $274.41, but opened at $308.01. West Pharmaceutical Services shares last traded at $314.2320, with a volume of 287,682 shares.

The medical instruments supplier reported $2.13 EPS for the quarter, topping the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The company’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS.

West Pharmaceutical Services Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 6th. Stockholders of record on Wednesday, April 29th will be paid a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is 12.96%.

West Pharmaceutical Services announced that its Board of Directors has approved a stock buyback program on Tuesday, February 17th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q1 results beat expectations: EPS $2.13 vs. $1.68 consensus and revenue $844.9M vs. ~$779.7M consensus; revenue up ~21% year‑over‑year, driving the immediate market reaction. WST Stock Jumps on Q1 Earnings & Sales Beat, EPS View Up on HVP Growth
• Positive Sentiment: Company raised guidance: FY2026 EPS raised to $8.40–$8.75 (vs. ~7.99 consensus) and Q2 EPS to $2.05–$2.12; revenue guide also nudged higher — a clear earnings‑driven catalyst supporting higher valuations. West Reports First-Quarter 2026 Results
• Positive Sentiment: Management cited strong demand for proprietary high‑value products (syringes, cartridges and other packaging components), which is lifting sales mix and expanding margins — a qualitative driver behind the raised profit outlook. West Pharma lifts 2026 profit forecast on strong demand for medical equipment
• Neutral Sentiment: Company posted investor materials and the conference‑call transcript/slide deck — useful for investors who want color on margin drivers, product cadence and reorder visibility but not new market moving data. View Press Release / Slide Deck

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on WST shares. UBS Group reissued a “buy” rating and set a $340.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research note on Friday, January 9th. Evercore decreased their price target on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 3rd. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $315.00 price objective on shares of West Pharmaceutical Services in a research report on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $315.67.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC raised its holdings in West Pharmaceutical Services by 3.7% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 1,091 shares of the medical instruments supplier’s stock valued at $286,000 after acquiring an additional 39 shares during the last quarter. NewEdge Wealth LLC raised its holdings in West Pharmaceutical Services by 3.5% in the 3rd quarter. NewEdge Wealth LLC now owns 1,174 shares of the medical instruments supplier’s stock valued at $333,000 after acquiring an additional 40 shares during the last quarter. Darwin Wealth Management LLC grew its stake in shares of West Pharmaceutical Services by 10.8% during the 4th quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock valued at $113,000 after buying an additional 40 shares during the period. RFG Advisory LLC grew its stake in shares of West Pharmaceutical Services by 2.2% during the 3rd quarter. RFG Advisory LLC now owns 2,233 shares of the medical instruments supplier’s stock valued at $586,000 after buying an additional 47 shares during the period. Finally, Aptus Capital Advisors LLC grew its stake in shares of West Pharmaceutical Services by 5.5% during the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after buying an additional 47 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Price Performance

The company’s 50 day moving average price is $252.00 and its 200-day moving average price is $262.10. The company has a market capitalization of $22.29 billion, a PE ratio of 45.54, a PEG ratio of 2.92 and a beta of 1.15. The company has a current ratio of 3.02, a quick ratio of 2.34 and a debt-to-equity ratio of 0.06.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.